Gilead GS-342-1553 A randomized, open-label study to evaluate the efficacy and safety of Sofosbuvir/GS-5816 Fixed Dose Combination - Ribavirin for 24 weeks in Chronic HCV infected subjects who participated in a prior Gilead-sponsored HCV study.
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Gilead Sciences, Inc.
Start Date
November 1, 2014
End Date
May 2, 2017
Administered By
Medicine, Gastroenterology
Awarded By
Gilead Sciences, Inc.
Start Date
November 1, 2014
End Date
May 2, 2017